MA40968A - Polythérapie à base d'anticorps anti-egfr - Google Patents

Polythérapie à base d'anticorps anti-egfr

Info

Publication number
MA40968A
MA40968A MA040968A MA40968A MA40968A MA 40968 A MA40968 A MA 40968A MA 040968 A MA040968 A MA 040968A MA 40968 A MA40968 A MA 40968A MA 40968 A MA40968 A MA 40968A
Authority
MA
Morocco
Prior art keywords
antibodies
polytherapy
egfr antibody
adc
antibody
Prior art date
Application number
MA040968A
Other languages
English (en)
Inventor
Ilia Alexandre Tikhomirov
Original Assignee
Formation Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formation Biologics Inc filed Critical Formation Biologics Inc
Publication of MA40968A publication Critical patent/MA40968A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Les anticorps anti-egfr peuvent être combinés pour améliorer leur effet anticancéreux. Dans la présente invention, au moins l'un de deux anticorps nus dans une combinaison est fourni en tant que conjugué de médicament d'anticorps (adc) dans lequel l'anticorps est couplé à une cytotoxine. Les deux anticorps peuvent également être fournis sous forme d'adc. Le résultat est une activité améliorée, l'amélioration étant synergique dans de nombreuses paires d'anticorps de ce type.
MA040968A 2014-10-31 2015-10-30 Polythérapie à base d'anticorps anti-egfr MA40968A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462073380P 2014-10-31 2014-10-31

Publications (1)

Publication Number Publication Date
MA40968A true MA40968A (fr) 2017-10-04

Family

ID=55856303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040968A MA40968A (fr) 2014-10-31 2015-10-30 Polythérapie à base d'anticorps anti-egfr

Country Status (5)

Country Link
US (1) US20170333570A1 (fr)
EP (1) EP3223857A4 (fr)
CA (1) CA2965362A1 (fr)
MA (1) MA40968A (fr)
WO (1) WO2016065456A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI750194B (zh) * 2016-07-05 2021-12-21 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｇｆｒ抗體-藥物偶聯物及其在醫藥上的應用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1549344T1 (sl) * 2002-10-10 2015-05-29 Merck Patent Gmbh FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1
WO2008104183A2 (fr) * 2007-03-01 2008-09-04 Symphogen A/S Compositions d'anticorps recombinants dirigés contre le récepteur du facteur de croissance épidermique
MX2012012441A (es) * 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
AU2011320314B2 (en) * 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
PT2668209T (pt) * 2011-01-24 2021-04-07 Gilead Sciences Inc Anticorpos seletivos para células que apresentam egfr em alta densidade
EA201991268A3 (ru) * 2011-03-29 2020-01-31 Иммуноджен, Инк. Получение конъюгатов "майтансиноид-антитело" одностадийным способом
SG11201402343SA (en) * 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
KR102305226B1 (ko) * 2013-03-15 2021-09-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형

Also Published As

Publication number Publication date
CA2965362A1 (fr) 2016-05-06
EP3223857A4 (fr) 2018-06-27
WO2016065456A1 (fr) 2016-05-06
US20170333570A1 (en) 2017-11-23
EP3223857A1 (fr) 2017-10-04

Similar Documents

Publication Publication Date Title
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
MA39034A1 (fr) Composés de quinoline sélectivement substitués
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201591402A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
ECSP16068524A (es) Insulina de acción prolongada y uso de la misma
PE20141019A1 (es) Nuevos inmunoconjugados
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA39254A1 (fr) Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
WO2018067520A3 (fr) Procédés et agents thérapeutiques
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
CL2018000131A1 (es) Inmunoconjugados de il22
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
EP4293116A3 (fr) Fibrinogène liquide stable
MA52076A (fr) Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1
EA201992883A1 (ru) АНТИТЕЛА К TrkB
MA40968A (fr) Polythérapie à base d'anticorps anti-egfr